EXHIBIT 99.1 Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance Announces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) May 1, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ...

Surmodics, Inc (NASDAQ:SRDX) Q4 2023 Earnings Conference Call February 2, 2024 8:00 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Tim J. Arens - Senior Vice President of Finance and Information Technology and Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets. Mike Matson - Needham James Sidoti - Sidoti & Company Operator Welcome everyone to the Surmodics First Quarter of Fiscal Year 2024 Earnings Call. Please note that this cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as specified in its charter) MINNESOTA 41-1356149 (State or other jurisdiction of incorporation or organization ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 0-23837 Surmodics, Inc. (Exact name of Registrant as specified in its Charter) Minnesota 41-1356149 (State or other ju ...

Surmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Gary Maharaj - President & Chief Executive Officer Tim Arens - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company Mike Matson - Needham & Company. Operator Welcome everyone to Surmodics Fourth Quarter and Fiscal Year 2023 Earnings Call. Please note that this call is being webcast. The we ...

1 Gary Maharaj President and CEO Tim Arens Senior Vice President of Finance, IT and CFO November 2023 © 2023 Surmodics, Inc. All r ...

Surmodics, Inc. (NASDAQ:SRDX) Q3 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Gary Maharaj - President & Chief Executive Officer Timothy Arens - Chief Financial Officer Conference Call Participants Brooks O’Neil - Lake Street Capital Markets Michael Matson - Needham & Company Michael Petusky - Barrington Research James Sidoti - Sidoti & Company Operator Welcome everyone to Surmodics Third Quarter of Fiscal Year 2023 Earnings Call. Please note that this call is being webcast. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as specified in its charter) MINNESOTA 41-1356149 (State or other jurisdiction of incorporation or organization) (I ...

Surmodics, Inc (NASDAQ:SRDX) Q2 2023 Results Conference Call April 26, 2022 8:00 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Timothy Arens - Chief Financial Officer Conference Call Participants Brooks O’Neil - Lake Street Capital Markets Michael Petusky - Barrington Research James Sidoti - Sidoti & Company Operator Welcome everyone to Surmodics’ Second Quarter and Fiscal Year 2023 Earnings Call. Please note that this call is being webcast. The webcast is accessible throug ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as specified in its charter) MINNESOTA 41-1356149 (State or other jurisdiction of incorporation or organization) ( ...